RE: Skinbiotix5 May 2022 08:46
Thank you both for you replies, and I agree with both. I believe Axis (from the RNS) has been slower than we all thought to begin with, however this will depend on the 60-70% retention rate, if this is maintained going forward then momentum should propel those revenue figures.
Any update on Croda/Skinbiotix will really getting everyone excited IMO, at the current price the share is a steal, but an update is still yet to come but I am confident in this part of the business. I believe that if we get a positive update here and Axisbiotix finally reaches the £1.2m forecast within this current calendar year, we could see prices over 100p.